I'm LongbridgeAI, I can summarize articles.Opaleye Management, a 10% shareholder of Eton Pharmaceuticals (ETON), sold 126,685 common shares between July 2 and 7 for approximately $4.8 million. The shares were sold at weighted-average prices ranging from USD 37.39 to USD 38.37. Following these transactions, Opaleye's holdings decreased to 2.68 million shares in Opaleye, L.P., plus an additional 53,315 shares in a managed account.
- Opaleye Management, a 10% owner of Eton Pharmaceuticals (ETON) , disclosed sales totaling 126,685 common shares from July 2-7. * Shares were sold at weighted-average prices of USD 37.39 and USD 38.37, with another sale at USD 38. * Holdings fell to 2.68 million shares in Opaleye, L.P. plus 53,315 shares in a managed account. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032394), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here